JP6207836B2 - 望ましくない細胞増殖と関連する疾患の治療のための治療剤 - Google Patents

望ましくない細胞増殖と関連する疾患の治療のための治療剤 Download PDF

Info

Publication number
JP6207836B2
JP6207836B2 JP2012502710A JP2012502710A JP6207836B2 JP 6207836 B2 JP6207836 B2 JP 6207836B2 JP 2012502710 A JP2012502710 A JP 2012502710A JP 2012502710 A JP2012502710 A JP 2012502710A JP 6207836 B2 JP6207836 B2 JP 6207836B2
Authority
JP
Japan
Prior art keywords
lif
cells
cancer
cell
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012502710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522756A (ja
JP2012522756A5 (https=
Inventor
スアレス，ホアン セオアネ
スアレス，ホアン セオアネ
プリエト，シルビア ペヌエラス
プリエト，シルビア ペヌエラス
トルレス，ホセ バセルガ
トルレス，ホセ バセルガ
Original Assignee
フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ
フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ
フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル ヘブロン
フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル ヘブロン
フンダシオ プリバーダ インスティトゥト デ レセルカ ホスピタル ウニベルシタリ バル ヘブロン
フンダシオ プリバーダ インスティトゥト デ レセルカ ホスピタル ウニベルシタリ バル ヘブロン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ, フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ, フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル ヘブロン, フンダシオ プリバーダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル ヘブロン, フンダシオ プリバーダ インスティトゥト デ レセルカ ホスピタル ウニベルシタリ バル ヘブロン, フンダシオ プリバーダ インスティトゥト デ レセルカ ホスピタル ウニベルシタリ バル ヘブロン filed Critical フンダシオ プリバーダ インスティトゥシオ カタラナ デ レセルカ イ エストゥディス アバンカッツ
Publication of JP2012522756A publication Critical patent/JP2012522756A/ja
Publication of JP2012522756A5 publication Critical patent/JP2012522756A5/ja
Application granted granted Critical
Publication of JP6207836B2 publication Critical patent/JP6207836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
JP2012502710A 2009-04-03 2010-04-06 望ましくない細胞増殖と関連する疾患の治療のための治療剤 Active JP6207836B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
ESP200900928 2009-04-03
PCT/EP2010/054499 WO2010115868A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015178986A Division JP2016040255A (ja) 2009-04-03 2015-09-11 望ましくない細胞増殖と関連する疾患の治療のための治療剤

Publications (3)

Publication Number Publication Date
JP2012522756A JP2012522756A (ja) 2012-09-27
JP2012522756A5 JP2012522756A5 (https=) 2013-05-23
JP6207836B2 true JP6207836B2 (ja) 2017-10-04

Family

ID=42342718

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012502710A Active JP6207836B2 (ja) 2009-04-03 2010-04-06 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2015178986A Pending JP2016040255A (ja) 2009-04-03 2015-09-11 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2018152551A Pending JP2019006784A (ja) 2009-04-03 2018-08-14 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2020016672A Pending JP2020090522A (ja) 2009-04-03 2020-02-04 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2021186785A Active JP7197665B2 (ja) 2009-04-03 2021-11-17 望ましくない細胞増殖と関連する疾患の治療のための治療剤

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015178986A Pending JP2016040255A (ja) 2009-04-03 2015-09-11 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2018152551A Pending JP2019006784A (ja) 2009-04-03 2018-08-14 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2020016672A Pending JP2020090522A (ja) 2009-04-03 2020-02-04 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2021186785A Active JP7197665B2 (ja) 2009-04-03 2021-11-17 望ましくない細胞増殖と関連する疾患の治療のための治療剤

Country Status (24)

Country Link
US (4) US10100112B2 (https=)
EP (2) EP3045474B1 (https=)
JP (5) JP6207836B2 (https=)
KR (6) KR20180079470A (https=)
CN (2) CN102574918A (https=)
AU (1) AU2010233791B2 (https=)
BR (1) BRPI1015369A2 (https=)
CA (1) CA2757680C (https=)
CY (1) CY1124148T1 (https=)
DK (1) DK3045474T3 (https=)
EA (1) EA201101450A1 (https=)
ES (2) ES2363358B1 (https=)
HR (1) HRP20210352T1 (https=)
HU (1) HUE054196T2 (https=)
IL (1) IL215467A (https=)
LT (1) LT3045474T (https=)
MX (1) MX336903B (https=)
PL (1) PL3045474T3 (https=)
PT (1) PT3045474T (https=)
SG (2) SG10202010568RA (https=)
SI (1) SI3045474T1 (https=)
SM (1) SMT202100153T1 (https=)
WO (1) WO2010115868A2 (https=)
ZA (1) ZA201107215B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1904093T3 (pl) * 2005-07-19 2018-12-31 Stemgen S.P.A. Hamowanie przez bmp-4 zdolności do tworzenia guzów przez komórki macierzyste guza
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
JP2017507969A (ja) * 2014-03-11 2017-03-23 ゴーダーヴァリ バイオリファイナリーズ リミテッド がん幹細胞標的化合物
CA3151221C (en) * 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
CN106687134A (zh) * 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
EP3273983B1 (en) 2015-03-23 2021-05-05 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP3555132B1 (en) * 2016-12-19 2023-11-15 Medimmune Limited Antibodies against lif and uses thereof
AU2019269131B2 (en) * 2018-05-14 2024-02-22 Fundació Privada Institució Catalana De Recerca I Estudis Avançats Antibodies against LIF and dosage forms thereof
MA52300A (fr) * 2018-06-18 2021-04-21 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Combinaison d'inhibiteurs de lif et d'agents anti-néoplasiques à base de platine à utiliser dans le traitement du cancer
AU2019291305B2 (en) * 2018-06-18 2024-03-21 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Methods for improving response to anti-LIF antibody treatment in individuals with cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
IL287220B2 (en) * 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies
CN120507517B (zh) * 2025-05-21 2026-04-10 浙江省肿瘤医院 用于评估宫颈癌鳞癌和腺癌特异性的预后分子标记物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
HU229520B1 (en) * 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
AR073231A1 (es) * 2008-08-29 2010-10-20 Genentech Inc Metodos diagnosticos y tratamientos para los tumores independientes del vegf (factor de crecimiento endotelial vascular)
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Also Published As

Publication number Publication date
EP2414394A2 (en) 2012-02-08
US20120114671A1 (en) 2012-05-10
KR102373754B1 (ko) 2022-03-15
SG10202010568RA (en) 2020-11-27
EP3045474A2 (en) 2016-07-20
PL3045474T3 (pl) 2021-08-09
US20190211095A1 (en) 2019-07-11
SG175032A1 (en) 2011-11-28
HRP20210352T1 (hr) 2021-05-28
PT3045474T (pt) 2021-03-22
CA2757680A1 (en) 2010-10-14
KR20220035978A (ko) 2022-03-22
ZA201107215B (en) 2012-12-27
DK3045474T3 (da) 2021-03-22
US11999782B2 (en) 2024-06-04
JP2020090522A (ja) 2020-06-11
US20200385455A1 (en) 2020-12-10
JP2022031742A (ja) 2022-02-22
JP2012522756A (ja) 2012-09-27
HUE054196T2 (hu) 2021-08-30
ES2363358B1 (es) 2012-06-21
KR20190093691A (ko) 2019-08-09
KR20180079470A (ko) 2018-07-10
AU2010233791B2 (en) 2016-01-21
BRPI1015369A2 (pt) 2021-06-29
JP2019006784A (ja) 2019-01-17
EP3045474A3 (en) 2016-09-28
JP2016040255A (ja) 2016-03-24
CN102574918A (zh) 2012-07-11
WO2010115868A3 (en) 2011-02-03
KR20170121319A (ko) 2017-11-01
CA2757680C (en) 2021-11-02
MX336903B (es) 2016-02-04
ES2363358A1 (es) 2011-08-01
EP3045474B1 (en) 2021-01-13
US10100112B2 (en) 2018-10-16
US20240400667A1 (en) 2024-12-05
IL215467A (en) 2016-06-30
KR20120100703A (ko) 2012-09-12
EA201101450A1 (ru) 2012-04-30
SI3045474T1 (sl) 2021-07-30
IL215467A0 (en) 2011-12-29
LT3045474T (lt) 2021-05-10
KR20200078668A (ko) 2020-07-01
CY1124148T1 (el) 2022-05-27
JP7197665B2 (ja) 2022-12-27
CN107964043A (zh) 2018-04-27
AU2010233791A1 (en) 2011-11-03
MX2011010425A (es) 2012-03-06
ES2864639T3 (es) 2021-10-14
WO2010115868A2 (en) 2010-10-14
SMT202100153T1 (it) 2021-05-07

Similar Documents

Publication Publication Date Title
JP7197665B2 (ja) 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP7410211B2 (ja) 望ましくない細胞増殖に関係する疾患の処置のための薬剤
HK1229338B (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1229338A1 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1172348A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
EA040048B1 (ru) Фармацевтическая композиция и способ лечения глиомы, характеризущейся наличием высоких уровней lif

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20130314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150911

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150928

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170906

R150 Certificate of patent or registration of utility model

Ref document number: 6207836

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250